Axsome Settles Investors' Drug Approval Suit For $7.8M
By Sydney Price · September 23, 2025, 8:23 PM EDT
Biopharmaceutical company Axsome Therapeutics Inc. and its shareholders have asked a New York federal court to approve a $7.75 million settlement to resolve investors' claims that Axsome hid issues related to...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login